» Articles » PMID: 10627455

Recombinant Human Interleukin-11 Synergizes with Steel Factor and Interleukin-3 to Promote Directly the Early Stages of Murine Megakaryocyte Development in Vitro

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2000 Jan 11
PMID 10627455
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The authors studied the role that interleukin (IL)-11 plays during the early stages of megakaryocyte (MK) development by investigating its in vitro effects on cell subpopulations enriched for bone marrow primitive progenitor cells and early and late committed progenitor cells. Progenitor subpopulations were isolated from bone marrow of normal or 5-fluorouracil (5FU)-treated mice and separated by sorting based on the surface antigens Sca-1, c-kit, and CD34. Functional analysis of the cell subpopulations, 5FU Lin(-)Sca-1(+)c-kit(+) or normal bone marrow (NBM) Lin(-)Sca-1(+)c-kit(+)CD34(-)cells, indicated that exposure of these cells to recombinant human (rh)IL-11 in combination with steel factor (SF) stimulates the formation of colonies in methylcellulose and their proliferation in single cell-containing liquid cultures. Kinetic studies of MK progenitor generation, in response to SF and rhIL-11, demonstrated that a significant number of the progenitors produced are committed to the MK lineage. RhIL-11 also synergized with both SF and IL-3 to stimulate MK colony growth from NBM Lin(-)Sca-1(+)c-kit(+) cells (early progenitors) and NBM Lin(-)Sca-1(-)c-kit(+) cells (committed late progenitors). In the presence of IL-3, NBM, Lin(-)Sca-1(-)c-kit(+) cells responded more strongly to rhIL-11 than SF. Consistent with these results is the observation that IL-11 receptor alpha chain mRNA is present in all the progenitor cells from which the MKs are derived. This cell culture and RNA analysis suggest that murine bone marrow primitive progenitor cells and early and late progenitor cells are direct targets of rhIL-11 and that rhIL-11 has the potential to promote megakaryocyte development at several very early stages. (Blood, 2000;95:503-509) (Blood. 2000;95:503-509)

Citing Articles

Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia.

Huang L, Xu J, Zhang H, Wang M, Zhang Y, Lin Q Ther Adv Hematol. 2023; 14:20406207231152746.

PMID: 36865986 PMC: 9972067. DOI: 10.1177/20406207231152746.


Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia.

Kumar B, Afshar-Kharghan V, Mendt M, Sackstein R, Tanner M, Popat U Front Immunol. 2022; 13:1018047.

PMID: 36203567 PMC: 9530569. DOI: 10.3389/fimmu.2022.1018047.


Transcriptomic analysis of early B-cell development in the chicken embryo.

Nuthalapati N, Evans J, Taylor R, Branton S, Nanduri B, Pharr G Poult Sci. 2019; 98(11):5342-5354.

PMID: 31237340 PMC: 6771548. DOI: 10.3382/ps/pez354.


Designer cytokine hyper interleukin 11 (H11) is a megakaryopoietic factor.

Dams-Kozlowska H, Kwiatkowska-Borowczyk E, Gryska K, Mackiewicz A Int J Med Sci. 2013; 10(9):1157-65.

PMID: 23869192 PMC: 3714392. DOI: 10.7150/ijms.5638.


The role of platelet factor 4 in radiation-induced thrombocytopenia.

Lambert M, Xiao L, Nguyen Y, Kowalska M, Poncz M Int J Radiat Oncol Biol Phys. 2011; 80(5):1533-40.

PMID: 21740995 PMC: 3134787. DOI: 10.1016/j.ijrobp.2011.03.039.